Piper Sandler Upgrades Capricor Therapeutics to Overweight, Raises Price Target to $25

Benzinga Newsdesk www.benzinga.com Positive 90.9%

Neg 0% Neu 0% Pos 90.9%

Piper Sandler analyst Edward Tenthoff upgrades Capricor Therapeutics (NASDAQ:CAPR) from Neutral to Overweight and raises the price target from $2 to $25.